Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 7.85B 6.8B 6.43B 5.82B 10.93B 753B 11.01B 76.75B 29.53B 382B 29.5B 28.84B 1,218B P/E 2026 *
-13.2x
P/E 2027 * -24.8x
Enterprise Value 7.75B 6.71B 6.35B 5.75B 10.78B 743B 10.87B 75.74B 29.14B 377B 29.11B 28.46B 1,202B EV / Sales 2026 *
8.41x
EV / Sales 2027 * 5.75x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-8.15%
1 week-16.68%
Current month-21.72%
1 month-17.45%
3 months-36.11%
6 months-33.63%
Current year-40.27%
1 week 46.72
Extreme 46.715
56.16
1 month 46.72
Extreme 46.715
64.19
Current year 46.72
Extreme 46.715
86.74
1 year 46.72
Extreme 46.715
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 A Others

Chief Technology Officer

110 0.0001%
8/31/26 A Others

Executive/Senior Manager

58 0.0000%
8/31/26 A Others

Founder

98 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-8.15%-16.68%-22.67%+10.11% 7.85B
+0.02%-0.07%-2.04%+26.70% 45.81B
-0.12%-1.19%+343.42%+545.03% 43.91B
+1.51%+4.04%+45.01%+27.38% 44.39B
-2.07%-1.42%+4.28%+72.97% 39.4B
-0.73%-3.06%+9.63%+38.92% 31.26B
-9.49%-11.23% - - 15.75B
+4.21%+5.01%+24.99%+121.62% 17.32B
+0.57%+4.14%+17.94%+34.28% 14.73B
-0.08%-2.81%+79.24%+31.27% 13.03B
Average -1.44%-2.75%+55.53%+100.92% 27.34B
Weighted average by Cap. -0.65%-1.67%+73.75%+130.23%

Financials

2026 *2027 *
Net sales 921M 798M 755M 683M 1.28B 88.39B 1.29B 9.01B 3.46B 44.82B 3.46B 3.38B 143B 1.38B 1.19B 1.13B 1.02B 1.92B 132B 1.93B 13.47B 5.18B 67.03B 5.18B 5.06B 214B
Net income -572M -495M -468M -424M -796M -54.86B -802M -5.59B -2.15B -27.82B -2.15B -2.1B -88.72B -320M -277M -262M -237M -445M -30.68B -448M -3.13B -1.2B -15.56B -1.2B -1.17B -49.61B
Net Debt -103M -89.21M -84.36M -76.37M -143M -9.88B -144M -1.01B -387M -5.01B -387M -378M -15.98B 68.31M 59.17M 55.95M 50.65M 95.07M 6.55B 95.78M 668M 257M 3.32B 257M 251M 10.6B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
15/09/26 $47.25 -8.15% 6,812,465
14/09/26 $51.44 -5.11% 5,974,753
11/09/26 $54.21 -2.59% 2,175,778
10/09/26 $55.65 -0.66% 3,057,309
09/09/26 $56.02 -1.22% 3,037,757
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
47.25USD
Average target price
83.82USD
Spread / Average Target
+77.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!